728-40-5 Purity
98%
If you have any other questions or need other size, please get a quote.
Specification
Barbatelli, G., et al. (2010). Am. J. Physiol. Endocrinol. Metab., 298, E1244-E1253.
Xamoterol hemifumarate serves as a selective beta1-adrenoceptor agonist to distinguish preadipocyte recruitment from white-to-brown adipocyte transdifferentiation in murine white adipose tissue upon cold stress, providing mechanistic insight into adipose plasticity.
Experimental Protocol: Female 129Sv mice received daily intraperitoneal injections of xamoterol hemifumarate (0.144 mg/kg) or the beta3-adrenoceptor agonist CL316,243 (0.1 mg/kg) for 3 or 5 days at room temperature. Subcutaneous white adipose tissue was harvested and processed for light microscopy, immunohistochemistry with anti-UCP1 antibody, and electron microscopy. Morphometric analysis quantified unilocular, paucilocular, and multilocular adipocytes, with preadipocyte density expressed as number per 100 adipocytes.
Performance Evaluation: Xamoterol administration increased only the number of preadipocytes in white adipose tissue, whereas CL316,243 induced the appearance of UCP1-immunoreactive brown adipocytes displaying paucilocular morphology. Cold exposure at 6 degrees C for 10 days increased brown adipocytes by 20-fold in subcutaneous white adipose tissue of wild-type mice, an effect that was blunted in beta3-adrenoceptor knockout animals. These findings demonstrate that beta1-adrenoceptor stimulation selectively mediates preadipocyte recruitment while beta3-adrenoceptor activation governs transdifferentiation of mature white adipocytes into brown adipocytes.
Humphrys, L.J., et al. (2024). bioRxiv, doi: 10.1101/2024.06.03.597093.
Xamoterol hemifumarate functions as a pharmacological probe to characterize beta-adrenoceptor subtype selectivity in a split nanoluciferase complementation-based mini-G protein recruitment assay using CRISPR/Cas9-modified HEK293T cells expressing tagged receptors at endogenous levels.
Experimental Protocol: HEK293T cells were genetically engineered using plasmid-based CRISPR/Cas9 to tag endogenous beta1- and beta2-adrenoceptors with NlucC fragments while replacing Galphas with NlucN-tagged minimal Gs protein. Concentration-response curves for xamoterol and standard agonists were generated in both overexpressed and CRISPR-modified native expression systems. Ligand-induced complementation of split luciferase fragments upon receptor-G protein interaction restored catalytic activity, producing bioluminescence upon furimazine substrate oxidation.
Performance Evaluation: In overexpressed systems, xamoterol acted as an antagonist at beta2-adrenoceptors but displayed weak partial agonist activity at beta1-adrenoceptors with a maximal efficacy of 14 plus-minus 1 percent relative to adrenaline. In the CRISPR/Cas9-modified endogenous system, xamoterol plateaued at a significantly higher level than with overexpression, enabling more accurate discrimination of partial agonist behavior. These results demonstrate that native receptor expression levels critically influence the pharmacological characterization of partial agonists.
The molecular formula of Xamoterol hemifumarate is C36H54N6O14.
The molecular weight of Xamoterol hemifumarate is 794.8 g/mol.
The IUPAC name of Xamoterol hemifumarate is (E)-but-2-enedioic acid;N-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]morpholine-4-carboxamide.
The InChIKey of Xamoterol hemifumarate is QEDVGROSOZBGOZ-WXXKFALUSA-N.
The canonical SMILES of Xamoterol hemifumarate is C1COCCN1C(=O)NCCNCC(COC2=CC=C(C=C2)O)O.C1COCCN1C(=O)NCCNCC(COC2=CC=C(C=C2)O)O.C(=CC(=O)O)C(=O)O.
The CAS number of Xamoterol hemifumarate is 73210-73-8.
Xamoterol hemifumarate has 10 hydrogen bond donor counts.
Xamoterol hemifumarate has 16 hydrogen bond acceptor counts.
Xamoterol hemifumarate has 18 rotatable bond counts.
The topological polar surface area of Xamoterol hemifumarate is 281Ų.
Please kindly note that our products are for research use only.
Download